CCT196969 (CCT-196969) is a novel, orally bioavailable, pan-RAF inhibitor (IC50 = 0.1 μM) with anti-SRC and anticancer activity.

Dabrafenib (formerly known as GSK2118436; GSK-2118436; GSK-2118436A; GSK-2118436B. Trade name: Tafinlar) is a novel, specific, orally bioavailable inhibitor of BRAF V600 mutants with potential anticancer activity.

PLX7904 (also known as PLX-7904; PB04; PB-04) is a novel potent and selective paradox-breaker B-Raf inhibitor with anticancer activity.

GDC-0879 (AR-00341677; GDC-0879; AR00341677) is a novel, potent, highly selective, and orally bioavailable B-Raf kinase inhibitor with potential antitumor activity.

RAF709 is a novel and potent inhibitor of the Raf kinase B/C isoforms (compound example 131 from patent WO2014151616A1) developed through a hypothesis-driven approach focusing on drug-like properties.

Belvarafenib (GDC-5573, HM95573, RG6185) is a novel, potent and selective inhibitor of the RAF (Rapidly Accelerated Fibrosarcoma) family kinases with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.

NVP-BHG712 (NVP BHG-712; NVP BHG712; BHG-712) is a selective and orally bioavailable EphB4 inhibitor with potential anticancer activity.

CID-25014542 is novel and potent inhibitor of Raf kinases with potential antineoplastic activity.

AD80 is a novel multikinase inhibitor that shows strong activity against human RET, BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR.

ZM 336372 (ZM-336372; ZM336372) is a novel, potent and selective c-Raf kinase inhibitor with potential anticancer activity.